Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease.

Abstract:

BACKGROUND:Crohn's disease (CD) is associated with depression. It is unclear if psychosocial interventions offer benefit for depressive symptoms during active CD. In this secondary analysis of a larger study of treating depression in pediatric inflammatory bowel disease, we assessed whether cognitive behavioral therapy (CBT) would differentiate from supportive nondirective therapy in treating depression and disease activity in youth with CD. We also explored whether somatic depressive symptoms showed a different pattern of response in the overall sample and the subset with active inflammatory bowel disease. METHODS:Youth with depression and CD (n = 161) were randomized to 3 months of CBT (teaching coping skills) or supportive nondirective therapy (supportive listening). Depressive severity was measured using the Children's Depression Rating Scale-Revised (CDRS-R) with the somatic depressive subtype consisting of those CDRS-R items, which significantly correlated with CD activity. Disease activity was measured by the Pediatric Crohn's disease Activity Index. Given the potential confound of higher dose steroids, subanalyses excluded subjects on >20 mg/d prednisone equivalent (n = 34). RESULTS:Total CDRS-R scores in the overall sample significantly decreased over time after both treatments (P < 0.0001). Treatment with CBT was associated with a significantly greater improvement in the Pediatric Crohn's disease Activity Index (P = 0.05) and somatic depressive subtype (P = 0.03) in those with active inflammatory bowel disease (n = 95) compared with supportive nondirective therapy. After excluding those on steroids (n = 34), there was a significant improvement in total CDRS-R (P = 0.03) and in Pediatric Crohn's disease Activity Index (P = 0.03) after CBT. CONCLUSIONS:Psychotherapy may be a useful adjunct to treat depression in the context of CD-related inflammation in youth who are not concurrently on higher dose steroids.

journal_name

Inflamm Bowel Dis

authors

Szigethy E,Youk AO,Gonzalez-Heydrich J,Bujoreanu SI,Weisz J,Fairclough D,Ducharme P,Jones N,Lotrich F,Keljo D,Srinath A,Bousvaros A,Kupfer D,DeMaso DR

doi

10.1097/MIB.0000000000000358

subject

Has Abstract

pub_date

2015-06-01 00:00:00

pages

1321-8

issue

6

eissn

1078-0998

issn

1536-4844

journal_volume

21

pub_type

杂志文章,随机对照试验
  • Endoscopic Balloon Dilation Size and Avoidance of Surgery in Stricturing Crohn's Disease.

    abstract:BACKGROUND:Endoscopic balloon dilation (EBD) is an effective method for treating stricture-related obstruction in Crohn's disease. We aimed to identify factors predictive of successful avoidance of surgery, including endoscopic features, in patients undergoing balloon dilation. METHODS:We performed a retrospective rev...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000001181

    authors: Reutemann BA,Turkeltaub JA,Al-Hawary M,Waljee AK,Higgins PDR,Stidham RW

    更新日期:2017-10-01 00:00:00

  • Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis.

    abstract:BACKGROUND:Recently, granulocyte and monocyte adsorption apheresis (GCAP) has been shown to be safe and effective for active ulcerative colitis (UC). We analyzed the safety and efficacy of GCAP (G-1 Adacolumn) in patients with steroid-refractory and -dependent UC. G-1 Adacolumn is filled with cellulose acetate carriers...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1097/00054725-200405000-00012

    authors: Naganuma M,Funakoshi S,Sakuraba A,Takagi H,Inoue N,Ogata H,Iwao Y,Ishi H,Hibi T

    更新日期:2004-05-01 00:00:00

  • Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease.

    abstract:BACKGROUND:Immunosuppressive therapy with anti-TNF-alpha antibodies is effective in patients with inflammatory bowel disease (IBD). However, there is an increased risk for infections associated with this therapy. METHODS:Here, we report the case of a 58-year-old patient with Crohn's disease (CD) treated with steroids ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20866

    authors: Beigel F,Jürgens M,Filik L,Bader L,Lück C,Göke B,Ochsenkühn T,Brand S,Seiderer J

    更新日期:2009-08-01 00:00:00

  • Healing of intestinal inflammation by IL-22.

    abstract::An interleukin (IL)-10 family cytokine, IL-22 is characterized by several unique biological properties, including 1) the target restricted to innate cells; 2) the distinct expression pattern between large and small intestines; 3) alteration of the cellular source depending on several factors; 4) the dual abilities to ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1002/ibd.22929

    authors: Mizoguchi A

    更新日期:2012-09-01 00:00:00

  • Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review.

    abstract:BACKGROUND:Nonadherence to medications may affect disease outcomes. The aim of this article was to review methods of assessment, prevalence, and predictors of nonadherence to anti-tumor necrosis factor therapy in inflammatory bowel diseases (IBD). METHODS:Studies were identified through the electronic database of MEDL...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0b013e31828132cb

    authors: Lopez A,Billioud V,Peyrin-Biroulet C,Peyrin-Biroulet L

    更新日期:2013-06-01 00:00:00

  • Effects of T cell-induced colonic inflammation on epithelial barrier function.

    abstract:BACKGROUND:Epithelial barrier disturbance is thought to contribute to the pathogenesis of inflammatory bowel diseases; however, it remains unclear whether it is a primary defect participating to the onset of inflammation or only a consequence of sustained inflammation. METHODS:A time course study of epithelial barrier...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21211

    authors: Suenaert P,Maerten P,Van Assche G,Van Driessche W,Geboes K,Bulteel V,Simaels J,Augustijns P,Ceuppens JL,Rutgeerts P,Perrier C

    更新日期:2010-08-01 00:00:00

  • Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease.

    abstract:BACKGROUND:Previous controversy was generated over the hypothesis that a paramyxovirus such as measles or vaccination against such viruses might be causally associated with inflammatory bowel disease (IBD). We aimed to determine if Crohn's disease (CD) or ulcerative colitis (UC) subjects are more likely to be seroposit...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20089

    authors: Bernstein CN,Rawsthorne P,Blanchard JF

    更新日期:2007-06-01 00:00:00

  • High Patient Activation Is Associated With Remission in Patients With Inflammatory Bowel Disease.

    abstract:BACKGROUND:High levels of patient activation (having the knowledge, skills, and confidence to effectively manage one's care), have been associated with improved outcomes in many chronic conditions. There have been few studies of the effects of activation in patients with inflammatory bowel disease (IBD). We performed a...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy378

    authors: Barnes EL,Long MD,Kappelman MD,Martin CF,Sandler RS

    更新日期:2019-06-18 00:00:00

  • Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD)-associated dysbiosis is characterized by a loss of Faecalibacterium prausnitzii, whose supernatant exerts an anti-inflammatory effect. However, the anti-inflammatory substances in F. prausnitzii supernatant and the mechanism in ameliorating colitis in IBD have not yet been fu...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy182

    authors: Zhou L,Zhang M,Wang Y,Dorfman RG,Liu H,Yu T,Chen X,Tang D,Xu L,Yin Y,Pan Y,Zhou Q,Zhou Y,Yu C

    更新日期:2018-08-16 00:00:00

  • Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.

    abstract:BACKGROUND:A notable proportion of patients with inflammatory bowel disease (IBD) are switched from infliximab (IFX) to adalimumab (ADL). We investigated if immunogenicity of IFX influenced immunogenicity and clinical outcomes of later ADL therapy. METHODS:Single-center cohort study including all patients with IBD ass...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1097/MIB.0000000000000138

    authors: Frederiksen MT,Ainsworth MA,Brynskov J,Thomsen OO,Bendtzen K,Steenholdt C

    更新日期:2014-10-01 00:00:00

  • Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn's Disease.

    abstract:BACKGROUND:Microbiota is most likely essential in the pathogenesis of Crohn's disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majority of patients experience endoscopic recurrence in the neoterminal ile...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa107

    authors: Olaisen M,Flatberg A,Granlund AVB,Røyset ES,Martinsen TC,Sandvik AK,Fossmark R

    更新日期:2021-01-01 00:00:00

  • Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease.

    abstract:Background:Both muscle-related complaints and elevated serum creatine kinase (CK) levels have been reported in patients with inflammatory bowel disease (IBD) treated with infliximab (IFX), mainly as case reports. The aim of this study was to investigate the effect of IFX therapy on serum CK levels in a cohort of Greek ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izy088

    authors: Theodoraki E,Orfanoudaki E,Foteinogiannopoulou K,Koutroubakis IE

    更新日期:2018-05-18 00:00:00

  • Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis.

    abstract:BACKGROUND/AIMS:The plant sterol guggulsterone has been shown to have anti-inflammatory properties. It remains unknown, however, whether guggulsterone is effective for the treatment of inflammatory bowel disease (IBD). Therefore, we investigated anti-inflammatory effects of guggulsterone on intestinal epithelial cells ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/01.mib.0000235830.94057.c6

    authors: Cheon JH,Kim JS,Kim JM,Kim N,Jung HC,Song IS

    更新日期:2006-12-01 00:00:00

  • Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis.

    abstract:BACKGROUND:We have developed a technique for measuring fecal excretion of human DNA by assuming that luminal desquamation of epithelial and inflammatory cells increases in damaged colonic mucosa. However, the clinical usefulness of this technique in the follow-up of patients with ulcerative colitis has not been establi...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20042

    authors: Casellas F,Borruel N,Antolín M,Varela E,Torrejón A,Armadans L,Guarner F,Malagelada JR

    更新日期:2007-04-01 00:00:00

  • The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease.

    abstract:BACKGROUND:Patients with inflammatory bowel disease (IBD) are more susceptible to mental health problems than the general population; however, temporal trends in psychiatric diagnoses' incidence or prevalence in the United States are lacking. We sought to identify these trends among patients with IBD using national Vet...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izz280

    authors: Thakur ER,Sansgiry S,Kramer JR,Waljee AK,Gaidos JK,Feagins LA,Govani SM,Dindo L,El-Serag HB,Hou JK

    更新日期:2020-08-20 00:00:00

  • Clinical epidemiology of Crohn's disease in Arabs based on the Montreal Classification.

    abstract:BACKGROUND:There has been a remarkable increase in the incidence of Crohn's disease (CD) among Arabs in recent years. We conducted this study to determine the clinical epidemiology of CD in Kuwait. METHODS:Sociodemographic and clinical information was collected for a continuous series of 206 Arab patients with CD and ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21890

    authors: Siddique I,Alazmi W,Al-Ali J,Al-Fadli A,Alateeqi N,Memon A,Hasan F

    更新日期:2012-09-01 00:00:00

  • Interleukin 10-deficient mice exhibit defective colonic Muc2 synthesis before and after induction of colitis by commensal bacteria.

    abstract::Germ-free (GF) interleukin 10-deficient (IL-10) mice develop chronic colitis after colonization by normal enteric bacteria. Muc2 is the major structural component of the protective colonic mucus. Our aim was to determine whether primary or induced aberrations in Muc2 synthesis occur in GF IL-10 mice that develop colit...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200411000-00016

    authors: Schwerbrock NM,Makkink MK,van der Sluis M,Büller HA,Einerhand AW,Sartor RB,Dekker J

    更新日期:2004-11-01 00:00:00

  • Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

    abstract:BACKGROUND:The aim of this study was to assess the clinical benefit and tolerability of adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with ulcerative colitis (UC). METHODS:Patients with active UC, including those who had lost response or developed intolerance to the chimeric...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20924

    authors: Afif W,Leighton JA,Hanauer SB,Loftus EV Jr,Faubion WA,Pardi DS,Tremaine WJ,Kane SV,Bruining DH,Cohen RD,Rubin DT,Hanson KA,Sandborn WJ

    更新日期:2009-09-01 00:00:00

  • Phenotype classification in IBD: Is there an impact on therapy?

    abstract::This review summarizes the current phenotypic classifications of inflammatory bowel disease (IBD) and outlines their implications for diagnosis, therapy, prognosis, clinical trial design, and genotype-phenotype correlations. ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20232

    authors: Walfish A,Sachar D

    更新日期:2007-12-01 00:00:00

  • The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity.

    abstract:BACKGROUND:Individuals with ulcerative colitis are at high risk of developing colitis-associated cancer. 5-Aminosalicylate (5-ASA) protects from cancer by its antiinflammatory activity as well as by altering cell growth, inducing apoptosis, and reducing replication errors. So far neither 5-ASA's structural specificity ...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.21112

    authors: Campregher C,Luciani MG,Biesenbach P,Evstatiev R,Lyakhovich A,Gasche C

    更新日期:2010-04-01 00:00:00

  • Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease.

    abstract:BACKGROUND AND AIMS:Crohn's disease (CD) is a chronic and invalidating inflammatory bowel disease of unknown etiology. The coordinated action of the cytochrome metabolizing subfamily CYP3A and the transport protein P-glycoprotein (P-gp) in the enterocyte results in a reduced bioavailability of drugs administered orally...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/00054725-200608000-00011

    authors: Fakhoury M,Lecordier J,Medard Y,Peuchmaur M,Jacqz-Agrain E

    更新日期:2006-08-01 00:00:00

  • Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study.

    abstract:BACKGROUND:CALM was a randomized phase 3 trial in patients with Crohn's disease (CD) that demonstrated improved endoscopic outcomes when treatment was escalated based on cutoffs for inflammatory biomarkers, fecal calprotectin (FC), C-reactive protein (CRP), and CD Activity Index (CDAI) remission vs CDAI response alone....

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izaa025

    authors: Reinisch W,Panaccione R,Bossuyt P,Baert F,Armuzzi A,Hébuterne X,Travis S,Danese S,Sandborn WJ,Schreiber S,Berg S,Zhou Q,Kligys K,Neimark E,Suleiman AA,D'Haens G,Colombel JF

    更新日期:2020-09-18 00:00:00

  • Adalimumab therapy in Crohn's disease of the ileal pouch.

    abstract:BACKGROUND:Crohn's disease (CD) of the pouch can develop in patients with ileal pouch-anal anastomosis, resulting in significant morbidities, even pouch failure. The aim of this study was to evaluate short- and long-term outcome of adalimumab (ADA) in treating these patients. METHODS:A total of 48 patients who receive...

    journal_title:Inflammatory bowel diseases

    pub_type: 临床试验,杂志文章

    doi:10.1002/ibd.22933

    authors: Li Y,Lopez R,Queener E,Shen B

    更新日期:2012-12-01 00:00:00

  • Impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal cytokines during remission in patients with Crohn's disease: a prospective study.

    abstract:BACKGROUND:Long-term enteral nutrition may maintain clinical and endoscopic remission in patients with Crohn's disease (CD). The aim of this prospective study was to investigate the impacts of long-term enteral nutrition on clinical and endoscopic disease activities and mucosal tissue cytokines in patients with quiesce...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1002/ibd.20238

    authors: Yamamoto T,Nakahigashi M,Saniabadi AR,Iwata T,Maruyama Y,Umegae S,Matsumoto K

    更新日期:2007-12-01 00:00:00

  • Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.

    abstract:BACKGROUND:Though vedolizumab has received regulatory approval for the treatment of Crohn's disease (CD) and ulcerative colitis (UC) in adults, there is increasing off-label use in children. AIMS:To describe the experience with vedolizumab in pediatric inflammatory bowel disease (IBD) patients at 3 tertiary IBD center...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,多中心研究

    doi:10.1097/MIB.0000000000000865

    authors: Singh N,Rabizadeh S,Jossen J,Pittman N,Check M,Hashemi G,Phan BL,Hyams JS,Dubinsky MC

    更新日期:2016-09-01 00:00:00

  • Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT).

    abstract:BACKGROUND:Outcomes are suboptimal in ulcerative colitis (UC). Telemedicine for UC is feasible and improves outcomes. Our goals were to evaluate a home telemanagement system for UC (UC HAT) on disease activity, quality of life (QoL), and adherence compared to best available care (BAC) in a randomized, controlled trial....

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ibd.21795

    authors: Cross RK,Cheevers N,Rustgi A,Langenberg P,Finkelstein J

    更新日期:2012-06-01 00:00:00

  • Development and Validation of a Confocal Laser Endomicroscopy-Based Score for In Vivo Assessment of Mucosal Healing in Ulcerative Colitis Patients.

    abstract:Background:Endoscopic monitoring is fundamental for evaluating the therapeutic response in IBD, but a validated endomicroscopic mucosal healing (MH) score is not available to date. However, confocal laser endomicroscopy (CLE) might define MH more precisely than conventional endoscopy. The major aim was to establish and...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1093/ibd/izx012

    authors: Hundorfean G,Chiriac MT,Mihai S,Hartmann A,Mudter J,Neurath MF

    更新日期:2017-12-19 00:00:00

  • Quantification and characterization of mucosa-associated and intracellular Escherichia coli in inflammatory bowel disease.

    abstract:BACKGROUND:Mucosa-associated Escherichia coli are abundant in inflammatory bowel disease (IBD), but whether these bacteria gain intracellular access within the mucosa is uncertain. If E. coli does gain intracellular access, the contribution of bacterial pathogenicity to this requires further elucidation. This study aim...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0b013e3182a38a92

    authors: Elliott TR,Hudspith BN,Wu G,Cooley M,Parkes G,Quiñones B,Randall L,Mandrell RE,Fagerquist CK,Brostoff J,Rayment NB,Boussioutas A,Petrovska L,Sanderson JD

    更新日期:2013-10-01 00:00:00

  • Immunochip analysis identification of 6 additional susceptibility loci for Crohn's disease in Koreans.

    abstract:BACKGROUND:Crohn's disease (CD) is an intractable inflammatory bowel disease of unknown cause. Recent genome-wide association studies of CD in Korean and Japanese populations suggested marginal sharing of susceptibility loci between Caucasian and Asian populations. As the 7 identified loci altogether explain 5.31% of t...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章

    doi:10.1097/MIB.0000000000000268

    authors: Yang SK,Hong M,Choi H,Zhao W,Jung Y,Haritunians T,Ye BD,Kim KJ,Park SH,Lee I,Kim WH,Cheon JH,Kim YH,Jang BI,Kim HS,Choi JH,Koo JS,Lee JH,Jung SA,Shin HD,Kang D,Youn HS,Taylor KD,Rotter JI,Liu J,McGovern

    更新日期:2015-01-01 00:00:00

  • Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis.

    abstract:BACKGROUND:The risk of corticosteroid-associated adverse events can limit the use of systemic corticosteroids. Oral, topically acting, second-generation corticosteroids that deliver drug to the site of inflammation, and biologic therapies, are effective treatment alternatives. The aim of this review was to evaluate the...

    journal_title:Inflammatory bowel diseases

    pub_type: 杂志文章,评审

    doi:10.1097/MIB.0000000000001261

    authors: Cross RK

    更新日期:2017-10-01 00:00:00